Cubist Systematic Strategies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Cubist Systematic Strategies’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$107K	Sell	70,609 -249,709	-78%	-$374K	﹤0.01%	2768
2025 Q2	$372K	Buy	320,318 +242,106	+310%	+$319K	﹤0.01%	2369
2025 Q1	$124K	Sell	78,212 -102,012	-57%	-$220K	﹤0.01%	2608
2024 Q4	$546K	Buy	+180,224	New	+$591K	﹤0.01%	2140
2022 Q4	–	Sell	-72,768	Closed	-$1.58M	–	4649
2022 Q3	$1.58M	Buy	+72,768	New	+$1.99M	0.01%	2230
2022 Q2	–	Sell	-7,958	Closed	-$367K	–	4606
2022 Q1	$367K	Buy	+7,958	New	+$429K	﹤0.01%	2719
2021 Q4	–	Sell	-6,968	Closed	-$464K	–	3668
2021 Q3	$464K	Buy	6,968 +6,551	+1,571%	+$378K	0.01%	2083
2021 Q2	$22K	Buy	+417	New	+$22.3K	﹤0.01%	2842
2021 Q1	–	Sell	-5,254	Closed	-$273K	–	2998
2020 Q4	$273K	Buy	+5,254	New	+$237K	﹤0.01%	2085

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's ZNTL Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Zentalis Pharmaceuticals (ZNTL) stake by 78% in Q3 2025, selling an estimated $374K and leaving 70,609 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

Cubist Systematic Strategies first reported a position in ZNTL in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.58M in Q3 2022. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Cubist Systematic Strategies held 70,609 shares of Zentalis Pharmaceuticals worth $107K as of Q3 2025.
Cubist Systematic Strategies sold 249,709 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $374K.
Zentalis Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2768 holding.
Cubist Systematic Strategies first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
Cubist Systematic Strategies's Zentalis Pharmaceuticals position peaked at $1.58M in Q3 2022.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.